[Recommendations for non-occupational postexposure HIV prophylaxis. Spanish Working Group on Non-Occupational Postexposure HIV Prophylaxis of the Catalonian Center for Epidemiological Studies on AIDS and the AIDS Study Group]. 2002

Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
Centre de Estudis Espidemiològics sobre la Sida a Catalunya. Hospital Universitari Germans Trias i Pujol. Badalona. España. jalmeda@ceescat.hugtip.scs.es

Evidence is lacking on the possible efficacy and effectiveness of non-occupational postexposure prophylaxis (PEP). However, because of its biological plausibility, the use of antiretroviral (ARV) drugs to prevent the development of infection in certain cases of accidental or sporadic exposure has begun to be considered as common clinical practice. Previous studies performed in Spain have demonstrated both the demand and the prescription of ARV as PEP and especially the diversity and inconsistency in the criteria used. In this context, in April of 2000 the Centre for Epidemiological Studies on AIDS of Catalonia (CEESCAT) (Department of Health and Social Security of the Autonomous Government of Catalonia), in collaboration with the National AIDS Plan and the AIDS Study Group (GESIDA), promoted the creation of a working group for the drafting of recommendations for PEP against HIV outside the occupational health context. The recommendations have been made bearing in mind the exceptional character of the exposure, the time elapsed since exposure, as well as evaluation of the risk of infection according to the type of exposure and the information available on the source of infection. In addition, the recommendations include the immediate measures necessary, as well as the preventive measures and clinical follow-up required both for HIV and for other infectious agents. All PEP regimens should be started within 72 hours of exposure and appropriate daily doses of two nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (PI), or two NRTIs and a non-nucleoside reverse transcriptase inhibitor (NNRTIs), should be administered for four weeks, bearing in mind the pharmacological and clinical situation of the source person. These recommendations should be updated periodically.

UI MeSH Term Description Entries
D007258 Informed Consent Voluntary authorization, by a patient or research subject, with full comprehension of the risks involved, for diagnostic or investigative procedures, and for medical and surgical treatment. Consent, Informed
D008297 Male Males
D011902 Rape Sexual intercourse without consent of the victim.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004781 Environmental Exposure The exposure to potentially harmful chemical, physical, or biological agents in the environment or to environmental factors that may include ionizing radiation, pathogenic organisms, or toxic chemicals. Exposure, Environmental,Environmental Exposures,Exposures, Environmental
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
December 1996, The Nurse practitioner,
Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
February 2009, Health technology assessment (Winchester, England),
Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
December 2008, European journal of medical research,
Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
May 2005, JAMA,
Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
November 1999, JAMA,
Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
December 2010, Topics in HIV medicine : a publication of the International AIDS Society, USA,
Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
February 2008, AIDS clinical care,
Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
October 1998, European journal of medical research,
Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
July 2000, Medicine and health, Rhode Island,
Jesús Almeda, and Jordi Casabona, and Alejandro Allepuz, and Felipe García-Alcaide, and Jorge del Romero, and Cristina Tural, and Joan Colm, and Ferrán Bolao, and Magda Campins, and Angela Domínguez, and Lluís Force, and Albert Giménez, and Luis Guerra-Romero, and
January 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA,
Copied contents to your clipboard!